← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

ASRT logoAssertio Holdings, Inc.(ASRT)Earnings, Financials & Key Ratios

ASRT•NASDAQ
$22.20
$143M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustrySpecialty pharma brand consolidators
AboutAssertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.Show more
  • Revenue$119M-5.0%
  • EBITDA$8M+525.9%
  • Net Income-$30M-36.7%
  • EPS (Diluted)-4.74-37.4%
  • Gross Margin70.19%+2.3%
  • EBITDA Margin7.13%+558.9%
  • Operating Margin-18.14%+7.4%
  • Net Margin-24.85%-43.9%
  • ROE-27.44%-64.7%
  • ROIC-13.83%+19.0%
  • Debt/Equity0.42+25.2%
  • Interest Coverage-7.00+13.0%
Technical→

ASRT Key Insights

Assertio Holdings, Inc. (ASRT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 99 (top 1%)
  • ✓Trading near 52-week high

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ASRT Price & Volume

Assertio Holdings, Inc. (ASRT) stock price & volume — 10-year historical chart

Loading chart...

ASRT Growth Metrics

Assertio Holdings, Inc. (ASRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-10.06%
5 Years1.9%
3 Years-8.75%
TTM-5%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-36.72%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-41.73%

Return on Capital

10 Years-16.48%
5 Years-20.39%
3 Years-40.87%
Last Year-13.92%

ASRT Recent Earnings

Assertio Holdings, Inc. (ASRT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Mar 16, 2026
EPS
$1.86
Est $3.05
+39.0%
Revenue
$14M
Est $6M
+118.5%
Q4 2025
Nov 10, 2025
EPS
$1.65
Est $1.20
+237.5%
Revenue
$49M
Est $6M
+697.9%
Q3 2025
Aug 11, 2025
EPS
$0.17
Est $0.10
-70.0%
Revenue
$29M
Est $29M
-0.3%
Q2 2025
May 12, 2025
EPS
$0.14
Est $0.06
-133.3%
Revenue
$26M
Est $28M
-3.7%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 16, 2026
$1.86vs $3.05+39.0%
$14Mvs $6M+118.5%
Q4 2025Nov 10, 2025
$1.65vs $1.20+237.5%
$49Mvs $6M+697.9%
Q3 2025Aug 11, 2025
$0.17vs $0.10-70.0%
$29Mvs $29M-0.3%
Q2 2025May 12, 2025
$0.14vs $0.06-133.3%
$26Mvs $28M-3.7%
Based on last 12 quarters of dataView full earnings history →

ASRT Peer Comparison

Assertio Holdings, Inc. (ASRT) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
PAHC logoPAHCPhibro Animal Health CorporationDirect Competitor2.38B58.6449.2827.37%6.29%30.81%2.67
AMRX logoAMRXAmneal Pharmaceuticals, Inc.Direct Competitor4.28B13.6261.918.05%2.39%7.47%0.13
SUPN logoSUPNSupernus Pharmaceuticals, Inc.Direct Competitor2.96B51.45-75.668.63%-3.74%-2.73%0.04
PRGO logoPRGOPerrigo Company plcDirect Competitor1.69B12.26-1.19-2.75%-43.5%-50.65%1.35
COLL logoCOLLCollegium Pharmaceutical, Inc.Direct Competitor1.18B36.5121.1023.62%8.05%24.11%3.12
HRMY logoHRMYHarmony Biosciences Holdings, Inc.Direct Competitor1.89B32.7812.1021.51%18.27%18.24%0.02
AVDL logoAVDLAvadel Pharmaceuticals plcDirect Competitor2.1B21.64-42.435.05%-0.11%-0.33%0.02
BHC logoBHCBausch Health Companies Inc.Product Competitor2.11B5.6513.148.53%-11.27%5.88%56.36

Compare ASRT vs Peers

Assertio Holdings, Inc. (ASRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PAHC

Most directly comparable listed peer for ASRT.

Scale Benchmark

vs CVS

Larger-name benchmark to compare ASRT against a more recognizable public peer.

Peer Set

Compare Top 5

vs PAHC, AMRX, SUPN, PRGO

ASRT Income Statement

Assertio Holdings, Inc. (ASRT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue380.72M311.77M229.53M108.08M111.01M156.23M152.07M124.96M118.71M
Revenue Growth %-16.49%-18.11%-26.38%-52.91%2.72%40.73%-2.67%-17.83%-5%
Cost of Goods Sold72.6M18.48M9.51M15.77M15.83M18.75M27.02M39.23M35.38M
COGS % of Revenue19.07%5.93%4.14%14.59%14.26%12%17.77%31.39%29.81%
Gross Profit
308.13M▲ 0%
293.29M▼ 4.8%
220.02M▼ 25.0%
92.3M▼ 58.0%
95.18M▲ 3.1%
137.49M▲ 44.4%
125.05M▼ 9.0%
85.73M▼ 31.4%
83.33M▼ 2.8%
Gross Margin %80.93%94.07%95.86%85.41%85.74%88%82.23%68.61%70.19%
Gross Profit Growth %-16.38%-4.81%-24.98%-58.05%3.12%44.45%-9.05%-31.44%-2.8%
Operating Expenses337.06M229.03M414.45M174.46M85.76M98.08M368.58M110.21M104.87M
OpEx % of Revenue88.53%73.46%180.57%161.42%77.25%62.78%242.38%88.2%88.34%
Selling, General & Admin195.69M119.22M110.44M104.22M56.55M48.1M69.74M76.95M69M
SG&A % of Revenue51.4%38.24%48.12%96.43%50.94%30.79%45.86%61.58%58.12%
Research & Development38.62M8.04M10.11M4.21M002.84M3.82M1.69M
R&D % of Revenue10.14%2.58%4.4%3.9%--1.87%3.06%1.42%
Other Operating Expenses102.75M101.77M293.9M66.03M29.2M49.98M296M29.44M34.18M
Operating Income
-42.18M▲ 0%
43.66M▲ 203.5%
-194.43M▼ 545.3%
-82.16M▲ 57.7%
9.42M▲ 111.5%
39.41M▲ 318.1%
-243.54M▼ 718.0%
-24.48M▲ 89.9%
-21.54M▲ 12.0%
Operating Margin %-11.08%14%-84.71%-76.02%8.49%25.22%-160.15%-19.59%-18.14%
Operating Income Growth %-272.1%203.51%-545.33%57.75%111.47%318.13%-718.03%89.95%12.01%
EBITDA63.32M150.09M-91.48M-55.72M38.54M72.8M-215.31M1.35M8.47M
EBITDA Margin %16.63%48.14%-39.86%-51.56%34.71%46.6%-141.59%1.08%7.13%
EBITDA Growth %-52.7%137.02%-160.95%39.09%169.16%88.91%-395.75%100.63%525.94%
D&A (Non-Cash Add-back)105.5M106.43M102.95M26.43M29.11M33.4M28.23M25.83M30M
EBIT-30.37M106.86M-5.11M-42.71M9.67M56.77M24.94M-20.68M-13.68M
Net Interest Income-73.55M-67.56M-58.39M-15.93M-10.22M-7.96M-3.38M182K-410K
Interest Income01.2M000003.22M2.67M
Interest Expense73.55M68.76M58.39M15.93M10.22M7.96M3.38M3.04M3.08M
Other Income/Expense-61.74M-5.68M-17.49M71.38M-9.98M-8.24M-10.52M2.95M-8.4M
Pretax Income
-103.92M▲ 0%
37.98M▲ 136.5%
-211.92M▼ 658.0%
-10.78M▲ 94.9%
-553K▲ 94.9%
31.17M▲ 5735.8%
-254.05M▼ 915.2%
-21.53M▲ 91.5%
-29.94M▼ 39.1%
Pretax Margin %-27.3%12.18%-92.33%-9.97%-0.5%19.95%-167.06%-17.23%-25.22%
Income Tax-1.43M1.07M5.28M17.37M728K-78.46M77.89M52K-435K
Effective Tax Rate %1.38%2.81%-2.49%-161.2%-131.65%-251.75%-30.66%-0.24%1.45%
Net Income
-102.5M▲ 0%
36.91M▲ 136.0%
-217.2M▼ 688.5%
-28.14M▲ 87.0%
-1.28M▲ 95.4%
109.63M▲ 8657.8%
-331.94M▼ 402.8%
-21.58M▲ 93.5%
-29.5M▼ 36.7%
Net Margin %-26.92%11.84%-94.63%-26.04%-1.15%70.17%-218.28%-17.27%-24.85%
Net Income Growth %-15.53%136.01%-688.49%87.04%95.45%8657.77%-402.8%93.5%-36.72%
Net Income (Continuing)-102.5M36.91M-217.2M-28.14M-1.28M109.63M-331.94M-21.58M-29.5M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)
-98.10▲ 0%
34.50▲ 135.2%
-184.35▼ 634.3%
-16.05▲ 91.3%
-0.45▲ 97.2%
30.45▲ 6935.0%
-70.05▼ 330.0%
-3.45▲ 95.1%
-4.74▼ 37.4%
EPS Growth %-12.95%135.17%-634.35%91.29%97.22%6935.02%-330.05%95.07%-37.39%
EPS (Basic)-98.1034.65-184.35-16.05-0.4534.95-70.05-3.45-4.74
Diluted Shares Outstanding1.05M1.07M1.18M1.75M2.88M3.64M4.74M6.35M6.4M
Basic Shares Outstanding1.05M1.06M1.18M1.75M2.88M3.13M4.74M6.35M6.4M
Dividend Payout Ratio---------

ASRT Balance Sheet

Assertio Holdings, Inc. (ASRT) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets231.72M215.92M103.95M94.25M103.5M132.26M171.06M202.55M216.65M
Cash & Short-Term Investments128.09M110.95M42.11M20.79M36.81M64.94M73.44M100.05M63.41M
Cash Only128.09M110.95M42.11M20.79M36.81M64.94M73.44M50.59M10.23M
Short-Term Investments000000049.47M53.18M
Accounts Receivable72.48M37.21M42.74M44.35M43.75M45.36M47.66M54.12M120.11M
Days Sales Outstanding69.4943.5667.97149.78143.85105.96114.4158.08369.3
Inventory13.04M3.4M3.41M11.71M7.49M13.7M37.69M38.31M24.12M
Days Inventory Outstanding65.5767.09131.02271.04172.66266.64509.08356.45248.81
Other Current Assets0000608K0299K10.07M9.01M
Total Non-Current Assets806.9M716.95M423.22M209.02M223.05M281.65M115.36M82.18M50.32M
Property, Plant & Equipment13.02M13.06M3.5M4.39M2.26M881K2.04M1.71M444K
Fixed Asset Turnover29.23x23.86x65.64x24.61x49.08x177.34x74.58x73.03x267.37x
Goodwill000000000
Intangible Assets793.87M692.1M400.54M200.08M216.05M198M111.33M80.47M48.91M
Long-Term Investments011.78M13.06M1.58M1.58M268K000
Other Non-Current Assets07.81M6.12M2.97M3.15M2.3M1.99M1K972K
Total Assets
1.04B▲ 0%
932.87M▼ 10.2%
527.17M▼ 43.5%
303.27M▼ 42.5%
326.55M▲ 7.7%
413.91M▲ 26.8%
286.42M▼ 30.8%
284.73M▼ 0.6%
266.97M▼ 6.2%
Asset Turnover0.37x0.33x0.44x0.36x0.34x0.38x0.53x0.44x0.44x
Asset Growth %-15.24%-10.18%-43.49%-42.47%7.67%26.75%-30.8%-0.59%-6.24%
Total Current Liabilities224.4M124.9M184.55M132.69M135.02M95.32M93.44M114.69M127.51M
Accounts Payable14.73M6.14M16.19M14.81M6.68M5.99M13.44M14.74M9.01M
Days Payables Outstanding74.07121.26621.82342.69154.12116.64181.54137.1292.99
Short-Term Debt82.5M120M80M11.94M12.17M470K000
Deferred Revenue (Current)135.83M-2.37M86.27M000000
Other Current Liabilities13.29M2.71M-82.5M20.02M47.65M30.36M6.09M96.36M118.5M
Current Ratio1.03x1.73x0.56x0.71x0.77x1.39x1.83x1.77x1.70x
Quick Ratio0.97x1.70x0.54x0.62x0.71x1.24x1.43x1.43x1.51x
Cash Conversion Cycle60.99-10.61-422.8378.13162.39255.97441.94377.41525.12
Total Non-Current Liabilities644.71M587.63M284.66M115.07M89.11M92.87M54.97M48.96M45.51M
Long-Term Debt544.23M446.11M271.26M72.16M61.32M66.4M38.21M38.81M39.12M
Capital Lease Obligations004.82M2.81M397K01.47M1.12M0
Deferred Tax Liabilities000004.27M4.55M00
Other Non-Current Liabilities14.3M20.39M8.58M40.1M27.4M22.2M10.74M9.03M6.38M
Total Liabilities869.11M712.53M469.21M247.76M224.13M188.19M148.42M163.65M173.02M
Total Debt626.73M566.11M358.17M89.6M75.87M66.87M39.68M40.27M39.12M
Net Debt498.64M455.16M316.06M68.81M39.06M1.93M-33.77M-10.32M28.89M
Debt / Equity3.70x2.57x6.18x1.61x0.74x0.30x0.29x0.33x0.42x
Debt / EBITDA9.90x3.77x--1.97x0.92x-29.76x4.62x
Net Debt / EBITDA7.87x3.03x--1.01x0.03x--7.63x3.41x
Interest Coverage-0.57x0.63x-3.33x-5.16x0.92x4.95x-72.05x-8.05x-7.00x
Total Equity
169.51M▲ 0%
220.34M▲ 30.0%
57.96M▼ 73.7%
55.51M▼ 4.2%
102.41M▲ 84.5%
225.72M▲ 120.4%
138M▼ 38.9%
121.08M▼ 12.3%
93.95M▼ 22.4%
Equity Growth %-32.41%29.98%-73.7%-4.22%84.48%120.4%-38.86%-12.26%-22.41%
Book Value per Share162.20205.8949.1831.7735.5961.9329.1419.0614.67
Total Shareholders' Equity169.51M220.34M57.96M55.51M102.41M225.72M138M121.08M93.95M
Common Stock313.86M6K8K3K4K5K9K9K1K
Retained Earnings-219.51M-182.6M-399.8M-427.94M-429.23M-319.6M-651.54M-673.12M-703.5M
Treasury Stock000000000
Accumulated OCI-5K-5K0000000
Minority Interest000000000

ASRT Cash Flow Statement

Assertio Holdings, Inc. (ASRT) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations62.17M72.5M90.47M-65.57M5.52M78.6M49.6M26.41M-28.18M
Operating CF Margin %16.33%23.25%39.42%-60.67%4.98%50.31%32.62%21.13%-23.74%
Operating CF Growth %-5.09%16.62%24.8%-172.48%108.42%1323.1%-36.89%-46.76%-206.72%
Net Income-102.5M36.91M-217.2M-28.14M-1.28M109.63M-331.94M-21.58M-30.38M
Depreciation & Amortization105.5M106.43M102.95M26.43M29.08M33.4M28.23M25.83M30M
Stock-Based Compensation13.02M12.59M10.6M10.92M3.54M7.5M9.16M5.01M3.45M
Deferred Taxes-8.72M1.27M-5.77M-8.42M0-80.38M76.2M00
Other Non-Cash Items36.53M22.51M200.51M-22.15M5.48M21.46M267.82M11.95M14.07M
Working Capital Changes18.34M-107.2M-606K-44.21M-31.29M-13.01M140K5.2M-45.33M
Change in Receivables30.14M35.27M-5.53M19.8M-11K-996K48.67M-6.46M-65.99M
Change in Inventory-1.87M9.05M-316K-291K4.27M-6.59M-4.97M-9.58M9.68M
Change in Payables-6.44M-33.61M-15.15M-36.48M-28.7M-10.11M-29.35M-1.26M-13.29M
Cash from Investing57.89M-7.08M-1.48M512.8M-18.52M-42.67M3.1M-48.91M-11.99M
Capital Expenditures-666K-5.51M-1.48M-10K-53K-274K-628K00
CapEx % of Revenue0.17%1.77%0.65%0.01%0.05%0.18%0.41%--
Acquisitions280K145K0506.81M-18.47M-42.4M1.53M00
Investments---------
Other Investing280K80K000000-8.17M
Cash from Financing-110.89M-81.35M-157.84M-468.55M29.03M-7.79M-44.2M-350K-189K
Debt Issued (Net)-110M-82.5M-153.25M-454.26M-9.84M-750K-10.5M00
Equity Issued (Net)1000K1000K-570K-778K1000K1000K-1000K-350K0
Dividends Paid000000000
Share Repurchases-753K-686K-570K-866K-418K-838K-7.9M-350K0
Other Financing-9.07M-184K-4.02M-13.52M-5.58M-13.23M-25.8M0-189K
Net Change in Cash
9.18M▲ 0%
-15.94M▼ 273.7%
-68.84M▼ 332.0%
-21.32M▲ 69.0%
16.02M▲ 175.2%
28.13M▲ 75.6%
8.5M▼ 69.8%
-22.85M▼ 368.9%
-40.36M▼ 76.6%
Free Cash Flow
61.5M▲ 0%
66.99M▲ 8.9%
88.99M▲ 32.8%
-65.58M▼ 173.7%
5.47M▲ 108.3%
78.32M▲ 1331.9%
48.98M▼ 37.5%
26.41M▼ 46.1%
-28.18M▼ 206.7%
FCF Margin %16.15%21.49%38.77%-60.68%4.93%50.13%32.21%21.13%-23.74%
FCF Growth %-1.82%8.93%32.85%-173.69%108.34%1331.88%-37.47%-46.08%-206.72%
FCF per Share58.8562.6075.51-37.531.9021.4910.344.16-4.40
FCF Conversion (FCF/Net Income)-0.61x1.96x-0.42x2.33x-4.31x0.72x-0.15x-1.22x0.96x
Interest Paid55.54M48.44M37.79M17.6M10.12M7.75M3.65M2.6M0
Taxes Paid121K6.47M4.4M0004.03M1.59M0

ASRT Key Ratios

Assertio Holdings, Inc. (ASRT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-31.36%-48.77%18.93%-156.1%-49.61%-1.62%66.82%-182.52%-16.66%-27.44%
Return on Invested Capital (ROIC)2.16%-4.33%4.87%-27.79%-24.73%5.32%16.01%-110.07%-17.08%-13.83%
Gross Margin80.83%80.93%94.07%95.86%85.41%85.74%88%82.23%68.61%70.19%
Net Margin-19.46%-26.92%11.84%-94.63%-26.04%-1.15%70.17%-218.28%-17.27%-24.85%
Debt / Equity2.87x3.70x2.57x6.18x1.61x0.74x0.30x0.29x0.33x0.42x
Interest Coverage0.29x-0.57x0.63x-3.33x-5.16x0.92x4.95x-72.05x-8.05x-7.00x
FCF Conversion-0.74x-0.61x1.96x-0.42x2.33x-4.31x0.72x-0.15x-1.22x0.96x
Revenue Growth33.02%-16.49%-18.11%-26.38%-52.91%2.72%40.73%-2.67%-17.83%-5%

ASRT SEC Filings & Documents

Assertio Holdings, Inc. (ASRT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 14, 2026·SEC

Material company update

Apr 9, 2026·SEC

Material company update

Mar 16, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 16, 2026·SEC

FY 2025

Mar 12, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 10, 2025·SEC

FY 2025

Aug 11, 2025·SEC

FY 2025

May 12, 2025·SEC

ASRT Frequently Asked Questions

Assertio Holdings, Inc. (ASRT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Assertio Holdings, Inc. (ASRT) reported $118.7M in revenue for fiscal year 2025. This represents a 39470% increase from $0.3M in 1996.

Assertio Holdings, Inc. (ASRT) saw revenue decline by 5.0% over the past year.

Assertio Holdings, Inc. (ASRT) reported a net loss of $29.5M for fiscal year 2025.

Dividend & Returns

Assertio Holdings, Inc. (ASRT) has a return on equity (ROE) of -27.4%. Negative ROE indicates the company is unprofitable.

Assertio Holdings, Inc. (ASRT) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.

Explore More ASRT

Assertio Holdings, Inc. (ASRT) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.